The global Acute Myeloid Leukemia (AML) Therapeutics Market is set to expand significantly, with projections indicating growth from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report by Fact.MR. This represents a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036, creating an absolute dollar opportunity of approximately USD 5.9 billion. The market is expected to nearly double in value as healthcare providers increasingly adopt genomics-driven treatment strategies and personalized medicine approaches.
Key market facts from the report include a market size of USD 3.8 billion in 2025, rising to USD 4.2 billion in 2026, and reaching USD 10.1 billion by 2036. Targeted therapies are the leading drug class, accounting for 36% of the market share, while newly diagnosed AML represents the largest disease type segment at 48%. Intravenous therapy dominates the route of administration with 52% share, hospitals lead end users at 55%, and hospital pharmacies account for 49% of sales channels. India is identified as the fastest-growing country at an 11.8% CAGR, followed by China at 10.9%.
The report highlights that precision medicine is revolutionizing AML treatment. Physicians are increasingly relying on molecular testing and genomic profiling to guide treatment decisions, with mutation-directed therapies targeting FLT3, NPM1, and other genetic abnormalities reshaping treatment standards. This shift enables more personalized care strategies, helping clinicians identify effective therapies for specific patient populations while reducing unnecessary toxicity.
Targeted therapies have emerged as the leading drug class, expected to hold 36% market share in 2026. The increasing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes, offering enhanced efficacy and improved tolerability compared to conventional treatments. As pharmaceutical companies develop next-generation targeted therapies, demand for precision oncology solutions is expected to strengthen over the coming decade.
Newly diagnosed AML is projected to hold 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Growing awareness, improved diagnostic capabilities, and wider access to specialized oncology services are contributing to increased treatment initiation rates across developed and emerging markets. Hospitals remain the leading end-user segment with 55% market share due to the intensive inpatient management required for AML treatment, including blood transfusion support, chemotherapy administration, and continuous monitoring. Similarly, hospital pharmacies maintain a dominant position with 49% market share due to the complexity of AML therapies and the need for specialized handling and administration protocols.
One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients with limited alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the treatment landscape, offering new hope for difficult-to-treat forms of AML.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations."
Regional markets display strong growth potential, with South Asia and East Asia emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending. Western Europe remains an important market supported by advanced hematology care centers and established reimbursement frameworks. Key country growth rates include India at 11.8% CAGR, China at 10.9%, the United States at 8.7%, Germany at 7.9%, and Japan at 7.4%.
The competitive landscape includes major pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. Industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, clinical trials, and patient access programs to strengthen their positioning and expand treatment accessibility.
The full report is available at Fact.MR's AML Therapeutics Market Report. A sample report with detailed forecasts, pricing trends, and strategic recommendations can be accessed here.
